Neuraptive Therapeutics, Inc.
Funding rounds
2 counted as startup funding. Open the number of investors for the round's details.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Neuraptive Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Oct 2022).
SEC Form D · Oct 2022
The industry group it chose in its notices: Biotechnology.
SEC Form D · Oct 2022
Products and services#
No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).
Investors#
No investor of Neuraptive Therapeutics, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Evan S Tzanis | Executive officer | Oct 2022 |
| Robert S Radie | Executive officer | Oct 2022 |
| David Jackson | Executive officer | Apr 2019 |
| David S Jackson | Director | Oct 2022 |
| David S Pierce | Director | Oct 2022 |
| Greg S Parekh | Director | Oct 2022 |
| Ivan S Gergel | Director | Oct 2022 |
| Randy S Hubbell | Director | Oct 2022 |
| Robert S Radie | Director | Oct 2022 |
| David Jackson | Director | Apr 2019 |
| Gino DiSciullo | Director | Apr 2019 |
| Greg Parekh | Director | Apr 2019 |
| Ivan Gergel | Director | Apr 2019 |
| Randy Hubbell | Director | Apr 2019 |